# Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)

> **NCT04170465** · PHASE2 · COMPLETED · sponsor: **Damanhour University** · enrollment: 70 (actual)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** Metformin Hydrochloride 850 mg Tablets
- **DRUG:** AC-T chemotherapy regimen

## Key facts

- **NCT ID:** NCT04170465
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-29
- **Primary completion:** 2022-04-02
- **Final completion:** 2022-06-28
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04170465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04170465, "Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04170465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*